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Abstract
Background: The coexistence of gastroesophageal reflux disease (GERD) and COPD has been recognized, but there
has been no comprehensive evaluation of the impact of GERD on COPD-related health status and patient-centered
outcomes.
Methods: Cross-sectional and longitudinal study of 4,483 participants in the COPDGene cohort who met GOLD
criteria for COPD. Physician-diagnosed GERD was ascertained by questionnaire. Clinical features, spirometry and
imaging were compared between COPD subjects without versus with GERD. We evaluated the relationship
between GERD and symptoms, exacerbations and markers of microaspiration in univariate and multivariate models.
Associations were additionally tested for the confounding effect of covariates associated with a diagnosis of GERD
and the use of proton-pump inhibitor medications (PPIs). To determine whether GERD is simply a marker for the
presence of other conditions independently associated with worse COPD outcomes, we also tested models
incorporating a GERD propensity score.
Results: GERD was reported by 29% of subjects with female predominance. Subjects with GERD were more likely
to have chronic bronchitis symptoms, higher prevalence of prior cardiovascular events (combined myocardial
infarction, coronary artery disease and stroke 21.3% vs. 13.4.0%, p < 0.0001). Subjects with GERD also had more
severe dyspnea (MMRC score 2.2 vs. 1.8, p < 0.0001), and poorer quality of life (QOL) scores (St. George’s Respiratory
Questionnaire (SGRQ) total score 41.8 vs. 34.9, p < 0.0001; SF36 Physical Component Score 38.2 vs. 41.4, p < 0.0001).
In multivariate models, a significant relationship was detected between GERD and SGRQ (3.4 points difference,
p < 0.001) and frequent exacerbations at baseline (≥2 exacerbation per annum at inclusion OR 1.40, p = 0.006).
During a mean follow-up time of two years, GERD was also associated with frequent (≥2/year exacerbations OR
1.40, p = 0.006), even in models in which PPIs, GERD-PPI interactions and a GERD propensity score were included.
PPI use was associated with frequent exacerbator phenotype, but did not meaningfully influence the
GERD-exacerbation association.
Conclusions: In COPD the presence of physician-diagnosed GERD is associated with increased symptoms, poorer
QOL and increased frequency of exacerbations at baseline and during follow-up. These associations are maintained
after controlling for PPI use. The PPI-exacerbations association could result from confounding-by-indication.
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Background
The association between gastroesophageal reflux (GERD)
and chronic obstructive pulmonary disease (COPD) has
been previously investigated [1]. Cross-sectional studies
with limited sample size have reported, with some exep-
tions, that esophageal disease-related symptoms are more
common and more severe in COPD patients than in other
general medicine patients [2-4]. Excess reflux, as deter-
mined by pH-monitoring, has also been documented to
be higher in COPD [5]. GERD has also been associated
with more frequent COPD exacerbations [6,7]. The cause
of this important association is unknown, but these data
suggest not only that is GERD more common in COPD,
but also that by increasing exacerbations, GERD may alter
COPD presentation and course.
We hypothesized that COPD patients with GERD would
have poorer QOL and more frequent exacerbations, but
that the use of GERD-controlling medications, proton-
pump inhibitors (PPIs) in particular, could modify these
associations. To test this hypothesis, in the current obser-
vational study, combining cross-sectional and longitudinal
data, we comprehensively evaluated clinical, physiologic
and imaging differences between COPD patients with ver-
sus without a physician-based diagnosis of GERD. We also
present an examination of how comorbid GERD impacts
different measures of COPD-related health status and
exacerbations.
Methods
Patient selection
The COPDGene Study (http://www.COPDGene.org/) is
an ongoing NHLBI-funded multicenter study of the gen-
etic epidemiology of smoking-related lung disease (Clinical
Trials Registration # NCT00608764). A complete descrip-
tion of the protocol has already been published [8]. Briefly,
inclusion criteria other than ability to give informed con-
sent are: age 45-80 years; at least 10 pack-years cigarette
smoking history; self-defined non-Hispanic white or
African-American ancestry; and willingness to undergo
study-related tests, including spirometry, CT scan of the
chest and blood collection for biomarker and genetic ana-
lysis. For the current analysis, we selected from the full co-
hort of 10,300 enrolled subjects participants with COPD,
both former or current smokers, who met criteria for
GOLD stage 1 or greater (fixed airflow obstruction with
a post-bronchodilator FEV1/FVC [forced vital capacity]
ratio ≤0.7),. Additionally, all subjects had CT measure-
ments of emphysema and airway abnormalities completed
at the time of data analysis. Parenchymal analysis was per-
formed using Slicer (www.Slicer.org); airway analysis was
performed using VIDA Pulmonary Workstation 2 (www.
vidadiagnostics.com). Lung areas with attenuation value of
less than-950 Hounsfield Units (HU) on the inspiratory
scans were considered emphysematous. CT-measurements
of airway disease included mean bronchial wall thick-
ness calculated as an average of six segmental values for
each subject, wall area percent (100* wall area/total
bronchial area) and the square root of the wall area of a
theoretical airway of 10 mm luminal perimeter (Pi10)
[8]. The research protocol was approved by the institu-
tional review board at each participating institution
(University of Michigan Health System Research Com-
mittee IRB approval HUM000014973, 07/16/2010), and
all participants provided written informed consent.
Data collection
Demographic data, smoking, and medical history were
collected using self-administered questionnaires. Symp-
toms and self-reported acute exacerbation frequency were
quantified using a modified version of the ATS Chronic
Respiratory Disease Questionnaire (ATS-DLD-78) [9] with
the question: “Have you had a flare-up of your chest
trouble in the last 12 months?” If the answer was “No”,
zero exacerbations were recorded, and when the answer
was “Yes”, additional questions on the presence, severity,
management and number of exacerbations followed. Dys-
pnea was assessed using the Modified Medical Research
Council scale [10], health-related QOL with the St.
George’s Respiratory Questionnaire (SGRQ) [11], Medical
Outcomes Study Short Form (SF) 36 version 2, and the
BODE index score was calculated for all patients [12]. Co-
morbidities were assessed based on subject self-report. At
enrollment all participants agreed to be contacted on a
regular basis and to provide information about develop-
ment of new exacerbations in the interval since the initial
visit, using the same initial questions. Participants were
followed longitudinally via either an automated telephone
or web-based system on an every 6-month basis. Subjects
not reached through the automated system were con-
tacted by a research coordinator for a phone-based inter-
view. Both baseline history of exacerbations as well as
exacerbations during longitudinal follow-up were dichoto-
mized on “frequent or infrequent”, based on the currently
accepted definition of ≥2 exacerbation per year [13].
Physiologic testing
Participants underwent spirometry pre- and post- admin-
istration of short-acting bronchodilating medication (albu-
terol), using the EasyOne™ spirometry system (Zurich,
Switzerland). Predictive values were obtained using
NHANES III data [14]. Quality control was performed
for all spirometry tests using both an automated system
and manual review. Six minute walk distance was mea-
sured in standard fashion [15].
Diagnosis of GERD and medication use
Ascertainment of physician-diagnosed GERD was based
on self-report. The patient was presented with the question
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“Have you ever been told by a physician that you have…”
and a list of different diseases, including GERD. Informa-
tion on medications, including GERD-related prescriptions
PPIs, antihistamines, antacids), was also collected.
Statistical analysis
Clinical characteristics between patients with and without
GERD were compared with t-tests or chi-square tests
where appropriate. Multivariate linear regression was used
to model SGRQ and MMRC scores. Given the skewed dis-
tribution of exacerbation frequency, we used a zero-
inflated Poisson model. All models were adjusted for age,
gender, current smoking history, BMI, FEV1% predicted
and clinical center. In the final models, we also evaluated
the influence of PPIs and of the GERD-PPIs interaction.
Because GERD could be a marker for the presence of
other serious diseases and conditions independently asso-
ciated with worse COPD outcomes, we also conducted
additional analyses to determine whether differences in
the GERD population as compared to the entire popula-
tion contributed to differences in outcomes. To better iso-
late the impact of GERD, we generated a covariate
representing the propensity to be diagnosed with GERD,
based on a logistic regression model. In this model, the re-
sponse variable of GERD diagnosis was generated, using
as predictors either the variables with association <0.10 in
univariate analysis or those accepted in the literature as
associated with GERD (age, gender, BMI, smoking history,
presence of cardiovascular disease, osteoporosis and gastric
ulcers) [16,17]. These estimated propensity scores were in-
cluded as a covariate in fully-adjusted regression models
for outcomes of interest. All statistical analyses were con-
ducted using STATA v.12 statistical software (College
Station, TX.). A p-value <0.05 was considered significant.
Results
GERD is associated with worse outcomes and greater use
of respiratory medications in COPD
Data were available for 4,483 participants who met GOLD
criteria for COPD, of any GOLD stage, and who had an-
swered the question of whether they had been previously
diagnosed by a physician as having GERD. Table 1 outlines
patient demographics, clinical characteristics, spirometry,
and disease impact (SGRQ, BODE, MMRC dyspnea score
and exacerbation frequency), stratified by history of
GERD. Physician-diagnosed GERD was reported by 29.1%
of the subjects, more frequently among women (50.9% vs.
41.3%, p < 0.0001) and older individuals (63.9 vs. 62.7 years
of age, p < 0.0001). Statistical differences of no clinical sig-
nificance were found in severity of airflow obstruction
among GERD subjects (56.3% vs. 57.9%, p = 0.02) as well
as those with higher BMI (28.8 kg/m2 vs. 27.5 kg/m2,
p <0.0001); the distribution by GOLD stages was also simi-
lar. Although those with GERD reported greater tobacco
consumption (53.4 vs. 50.0 pack-years, p = 0.003), they
were less frequently current smokers (34.3% vs. 47.1%,
Table 1 Demographics, spirometry, and clinical characteristics of COPD subjects stratified by history of GERD*
GERD (n = 1,307) No GERD (n =3,176) Total (n =4,483) P-value
Age (years) [mean (s.d.)] 63.9 (8.2) 62.7 (8.8) 63.1 (8.6) <0.0001
Gender (% female) 50.9 41.3 44.1 <0.0001
FEV1% predicted [mean (s.d.)] 56.3 (21.4) 57.9 (23.3) 57.4 (22.8) 0.02
Spirometry Gold Stage (%)
Stage 1-2 60.1 60.7 60.6
Stage 3-4 39.9 39.3 39.4 0.67
Body mass index (kg/m2) [mean (s.d.)] 28.8 (6.1) 27.5 (6.1) 27.9 (6.1) <0.0001
Current smoking (% of each group) 34.3 47.1 43.3 <0.0001
Pack years [mean (s.d.)] 53.4 (27.6) 50.8 (27.0) 51.6 (27.2) 0.003
Currently works (% patients) 24.4 28.0 26.9 0.01
Education beyond high school (% patients) 60.9 59.7 60.1 0.45
Chronic bronchitis (% patients) 29.0 24.7 25.9 0.002
Short-acting beta-agonists (% of patients) 61.0 48.5 52.1 <0.0001
Long-acting beta-agonists [LABA] (% of patients) 9.1 6.5 7.3 0.011
Inhaled corticosteroids [ICS] (% of patients) 13.9 9.3 10.6 <0.0001
Combination ICS/LABA (% of patients) 41.7 33.6 36.0 <0.0001
Long acting anti-muscarinic (% of patients) 40.2 30.8 33.5 <0.0001
Any GERD therapy (% of patients) 52.8 8.2 21.2 <0.0001
Proton Pump Inhibitors (% of patients) 46.8 6.5 18.2 <0.0001
*Means and standard deviations of the mean or percentages are presented; p-values represent t-test or chi-square comparison between groups.
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p < 0.0001). Compared to patients with COPD without
GERD, a greater frequency of subjects reporting coexistent
GERD also fulfilled the diagnostic criteria for chronic
bronchitis (29.0% vs. 24.7%, p = 0.002). Subjects with coex-
istent GERD were more frequently prescribed all classes
of COPD-related medications, including short-acting
medications (61.0% vs. 48.5%, p < 0.0001) and controller
medications (e.g. combined steroid and long-acting beta-
agonist 41.7% vs. 33.6%, p < 0.0001; long-acting anti-
muscarinics 40.2% vs. 30.8%, p < 0.0001).
GERD is associated with worse QOL and greater co-
morbidity in COPD
Significant differences were also noted in the impact of
GERD on QOL measures and exacerbations (Table 2).
Those with GERD had a shorter six minute walk distance
(1,192 vs. 1,250 feet, p < 0.0001); higher BODE index (2.7
vs. 2.4, p = 0.001), more severe MMRC dyspnea scores (2.2
vs. 1.8, p < 0.0001); higher total SGRQ score (41.8 points
vs. 34.9 points, p < 0.0001); lower SF36 PCS score (38.2 vs.
41.4 points, p < 0.0001), and more frequent exacerbations
in the year prior to enrollment (0.9 vs. 0.6, p < 0.0001).
Importantly, those with GERD more frequently reported
≥2 exacerbations in the prior year (22.5% vs. 12.9% of
those without GERD, p < 0.001).
COPD subjects with GERD also had significantly in-
creased frequency of comorbidities (Table 2). We found
significantly increased frequency of myocardial infarc-
tion (10.9% vs. 6.4%, p < 0.0001), coronary artery disease
(11.9% vs. 7.6%, p < 0.0001), angina (8.6% vs. 4.0%, p <
0.0001), as well as modifiable cardiovascular risk factors
(two or more of the following: hypertension, hyperlipid-
emia, obesity and smoking, 60.5% vs. 50.5%, p < 0.0001),
and sleep apnea (22.2% vs. 13.5%, p < 0.0001). By con-
trast, we found no differences in the reported frequency
of diabetes (13.5% vs. 11.7%, p = 0.22).
GERD is independently associated with worse QOL, more
frequent exacerbation of COPD & clinical but not
radiographic markers of microaspiration
After identifying the imbalance between GERD and no-
GERD patients in the distribution of demographics and
comorbid conditions, we generated a propensity score for
GERD diagnosis, as described in the Methods section.
Table 2 Comorbidities, disease impact and health-related quality-of-life stratified by history of GERD*
GERD
(n = 1,307)
No GERD
(n =3,176)
Total
(n = 4,483)
P-value
Comorbidities
Cardiovascular disease** 21.3 14.0 16.1 <0.0001
Congestive heart failure 5.7 4.1 4.6 0.01
Hypertension 55.7 45.2 48.3 <0.0001
Diabetes mellitus 13.5 11.7 12.3 0.08
Peripheral vascular disease 4.7 2.5 3.2 0.0001
Osteoporosis/Compression fractures 25.0 13.4 16.8 <0.0001
Any arthritis 28.6 15.8 19.5 <0.0001
Sleep apnea 22.2 13.5 16.1 <0.0001
2 or more modifiable risk factors*** 60.5 50.5 53.4 <0.0001
Disease impact and health-related quality-of-life
Six minute walk distance (feet) [mean (s.d.)] 1,192 (392) 1,250 (413) 1,233 (408) <0.0001
BODE [mean (s.d.)] 2.7 (2.0) 2.4 (2.1) 2.5 (2.1) 0.001
MMRC dyspnea score [mean (s.d.)] 2.2 (1.4) 1.8 (1.5) 1.9 (1.5) <0.0001
SGRQ total score [mean (s.d.)] 41.8 (22.3) 34.9 (22.9) 36.9 (22.9) <0.0001
SF-36 PCS 38.2 (10.4) 41.4 (11.2) 40.4 (11.0) <0.0001
SF-36 MCS 48.0 (13.2) 49.1 (12.3) 48.8 (12.6) 0.07
Exacerbation in the year prior to enrollment [mean (s.d.)] 0.9 (1.3) 0.6 (1.1) 0.7 (1.2) <0.0001
Hospitalized exacerbations in the year prior to enrollment (%) 22.0 18.6 19.5 0.008
Frequent exacerbator phenotype [>/=2 exacerbations per annum] (%) 22.5 12.9 15.7 <0.0001
Exacerbations per year during follow-up [mean (s.d.)] 0.9 (1.7) 0.6 (1.6) 0.7 (1.6) <0.0001
Frequent exacerbator phenotype during follow-up [>/=2 exacerbations per annum] (%) 17.9 14.7 16.9 <0.0001
*Percentages are presented; p-values represent chi-square comparison between groups.
**As a combination of Myocardial Infarction, Coronary Artery Disease, and Stroke/TIA.
***Modifiable cardiovascular disease risk factors include hypertension, hyperlipidemia, current smoking, and BMI > 30.
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This propensity score was well-balanced with respect to
the distribution of important covariates. Next, in separate
multivariate models, each controlling for age, gender,
BMI, current smoking and severity of airflow obstruction,
we examined the effect of GERD on health-related QOL
and exacerbation frequency in COPD. The three models
tested the independent effect of GERD (model 1); of
GERD plus propensity to be diagnosed with GERD (model
2); and with the addition of use of PPIs plus GERD-PPI
use interaction (model 3) (Table 3).
These analyses demonstrate that the presence of GERD
in COPD is associated with worse QOL, with an associ-
ated 3.4 point (95% CI 1.8, 4.9) higher SGRQ total score,
which is within the accepted minimal important difference
for this measure of health status [18].
Using data on enrollment, GERD in COPD is also as-
sociated with higher frequency of exacerbations in the
previous year (1.17 fold increase in frequency; 95% CI
1.05, 1.31; p = 0.005) and more risk of being a “frequent
exacerbator” (OR 1.40; 95% CI 1.10, 1.77; p = 0.006).
Additional analysis after a mean follow-up of two years
showed a sustained association between GERD and ex-
acerbation frequency fulfilling the definition of frequent
exacerbation (OR 1.40; 95% CI 1.10, 1.79; p = 0.006).
All models (Table 3, third column) include an analysis
of the effect of PPIs. They uniformly demonstrate that
Table 3 Multivariate models of the effect of GERD on different COPD outcomes among participants in COPDGene
(n = 4,483)*
Model 1 GERD diagnosis
Regression coefficient or
OR (95% CI)
Model 2 Additionally adjusted for
propensity to be diagnosed with
GERD Regression coefficient or OR (95% CI)
Model 3 Additionally adjusted for PPIs
use and GERD-PPIs Interaction
Regression coefficient or OR (95% CI)
Outcome: SGRQ score symptoms
GERD 7.40 (5.93, 8.87) 2.48 (1.01, 3.95) 3.40 (1.56, 5.22)
PPI use 4.19 (1.09, 7.28)
GERD*PPIs interaction (p-value) 0.006
Outcome: SGRQ score activity
GERD 6.35 (4.83, 7.81) 3.00 (1.46, 4.55) 3.82 (1.90, 5.75)
PPI use 3.63 (0.37, 6.88)
GERD*PPIs interaction (p-value) 0.021
Outcome: SGRQ score impact
GERD 5.48 (4.27, 6.69) 2.34 (1.10, 3.58) 3.09 (1.55, 4.64)
PPI use 3.75 (1.14, 6.36)
GERD*PPIs Interaction (p-value) 0.005
Outcome: SGRQ total score
GERD 6.05 (4.85, 7.26) 2.58 (1.36, 3.80) 3.38 (1.86, 4.90)
PPI use 3.77 (1.19, 6.34)
GERD*PPIs interaction (p-value) 0.003
Outcome: Count of exacerbations in the year prior to enrollment**
GERD 1.32 (1.21, 1.44) 1.16 (1.06, 1.27) 1.17 (1.05, 1.31)
PPI use 1.20 (1.00, 1.44)
GERD*PPIs interaction NS
Outcome: Frequent exacerbator at enrollment
GERD 1.88 (1.57, 2.24) 1.41 (1.17, 1.71) 1.40 (1.10, 1.77)
PPI use 1.60 (1.09, 2.35)
GERD*PPIs interaction NS
Outcome: Frequent exacerbator at follow-up
GERD 1.81 (1.52, 2.16) 1.50 (1.24, 1.82) 1.40 (1.10, 1.79)
PPI Use 1.56 (1.06, 2.30)
GERD*PPIs interaction NS
*All models additionally adjusted for age, gender, BMI, current smoking, FEV1% predicted and clinical center.
**Zero-inflated Poisson model.
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PPI use does not change the associations between GERD
and exacerbations and are actually associated with poor
outcomes. Further analysis of the interaction of GERD
by PPI use demonstrated significance only when model-
ing QOL, but not for exacerbations. In additional sensi-
tivity analyses we included in the propensity score and
all multivariate models the imbalance in the use of re-
spiratory medications, and there was not change in the
strength or the direction of the associations.
To explore hypothetical mechanistic explanations for
GERD-COPD outcome relationships, we also used our
data to examine two additional associations. First, we
looked for differences in indirect markers of recurrent
aspiration or microaspiration, and found all to be more
frequent among those with GERD: reported pneumonia
(58.1% vs. 43.9%, p < 0.0001); recurrent wheezing (69.8%
vs. 55.5%, p < 0.0001); and physician-diagnosed asthma
(28.8% vs. 20.0%, p < 0.0001). Second, we searched for
radiologic changes that might accompany GERD. This
analysis disclosed no differences between COPD patients
with versus without GERD in severity of emphysema, or
in any of the measures of airway thickness (Table 4).
Discussion
The analysis of a large cross-sectional multicenter study
of patients with a wide range of COPD severities pro-
vides evidence of a significant association between the
presence of GERD and both more symptomatic disease
and poorer health status. We found that GERD is fre-
quently found among COPD patients, and that COPD
patients with coexistent GERD experience worse QOL
(SGRQ), greater dyspnea (MMRC), and more frequent
exacerbations during follow-up. These associations were
maintained in multivariate analysis, independent of the
effect of age, gender, severity of airflow obstruction,
current smoking history and BMI. Importantly, these as-
sociations persisted after adjusting both for therapeutic
PPI use and for the imbalance of other covariates
associated with GERD diagnosis. Based on additional
analysis of the GERD-PPi use interaction (model 3), we
also discovered that PPIs use itself could be associated
with more frequent exacerbations, but also with im-
proved health-related QOL, as measured by SGRQ.
The 29.1% prevalence of physician-diagnosed GERD in
our population is higher than the 16.5% reported by Bor
[3], which used different disease-specific questionnaires; it
is lower than reports based on continuous esophageal pH
monitoring [5], but within the same range of other reports
based on frequency of symptoms [4] and self-report data
[19] in different clinical settings and in different countries
[20]. Our finding of a similar degree of airflow obstruction,
measured by FEV1% predicted, among COPD patients
regardless of GERD diagnosis agrees with and greatly
extends data presented in smaller series [2,5]. Interest-
ingly, even with similar spirometry values, our participants
with GERD had more intense bronchodilator and anti-
inflammatory treatment, most probably in response to
more frequent symptoms and exacerbations. The slightly
greater frequency of GERD in women with COPD agrees
with general population-based studies [21] and recent in-
quires of healthcare utilization in the US [22]. Whether
this greater frequency of GERD in women with COPD is
casually responsible of the established finding from mul-
tiple studies that women with COPD also suffer more fre-
quent exacerbations [23,24], is an important topic for
future investigation in this and other large longitudinal
studies.
Although anticipated, our finding that multiple comor-
bidities were significantly more frequent in COPD pa-
tients with GERD is significant given our standardized
physiological and radiographic characterization of COPD
phenotypes and the potential to look for genetic associ-
ation between COPD and its comorbidities in future ana-
lysis of this cohort. Those GERD-associated comorbidities
in COPD included cardiovascular diseases, both as mani-
festations of established disease (including myocardial
Table 4 Aspiration-related symptoms, and radiologic measurements stratified by history of GERD*
GERD (n = 1,307) No GERD (n =3,176) Total (n =4,483) P-value
History of Pneumonia (%) 58.1 43.9 48.1 <0.0001
Asthma (%) 28.8 20.0 22.6 <0.0001
Have a cough (%) 47.4 41.7 43.3 0.0004
Have wheezing (%) 69.8 55.5 59.7 <0.0001
CT calculated TLC, liters [mean (s.d.)] 5.9 (1.4) 6.0 (1.4) 6.0 (1.4) 0.003
Emphysema [mean (s.d.)] 11.9 (12.1) 11.3 (12.1) 11.5 (12.1) 0.20
Emphysema >20% (%) 23.9 22.9 23.2 0.12
% Gas trapping [mean (s.d.)] 35.9 (20.0) 35.4 (21.2) 35.5 (20.1) 0.40
Wall thickness in mm [mean (s.d.)] 62.4 (3.2) 62.4 (3.2) 62.4 (3.2) 0.90
Pi10 3.7 (0.1) 3.7 (0.1) 3.7 (0.1) 0.30
*Means and standard deviations of the mean or percentages are presented; p-values represent t-test or chi-square comparison between groups.
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infarction, coronary artery disease, stroke/TIA), as well as
cardiovascular risk factors (including obesity, current to-
bacco use, hypertension, and hyperlipidemia). Clustering
of these comorbidities could reflect shared risk factors
(obesity and diet) or a common inflammatory process, ul-
timately affecting the progression of COPD [25]. We also
tested if differences in our findings are explained by other
factors (e.g. sleep apnea), and found that the GERD-
COPD outcomes relations are maintained in the presence
or absence of sleep apnea (Additional file 1: Table S1). The
higher frequency of poor outcomes among participants
with GERD in our longitudinal study supports the clinical
suspicion that GERD could be an indicator of more fre-
quent comorbidities.
We attempted to overcome two major limitations of pre-
vious observational studies examining the association be-
tween GERD and COPD. The first is the already described
finding of clustering of comorbidities and poorer baseline
functional status of those with GERD, which complicates
isolating the effect of GERD alone. Hence, we performed a
propensity analysis to identify additional factors associated
with a diagnosis of GERD, and showed that the association
between GERD and worse COPD outcomes were main-
tained. A second novel feature of our study is that we ad-
justed for PPI use and GERD-PPI use interactions. The
independent association of PPI use with exacerbations and
QOL may be due to confounding-by-indication, such that
such individuals were deemed “sicker” by their physicians
and therefore more likely to receive PPI therapy for their
GERD. Our results overall, however, support a relationship
between GERD and poor COPD outcomes, even appropri-
ately controlling for the effect of medications.
It is noteworthy that our COPD patients with GERD
more frequently displayed clinical characteristics of the
chronic bronchitis predominant COPD phenotype re-
cently described using data from this same cohort [26].
Sputum production is gaining more acceptance as a pre-
dictor of increased risk for frequent exacerbations and
for response to specific therapies [27]. It is possible that
the presence of GERD increases bronchial inflammation
in COPD patients; however, we did not find a difference
in airway disease measures assessed via imaging between
those with GERD versus without GERD. Others have re-
ported an association between an inflammatory marker,
exhaled breath condensate pH, and GERD symptoms in
COPD patients [4], but further studies are needed to
understand fully this potential relationship and its po-
tential treatment implications.
The finding that GERD in COPD patients was associ-
ated with poorer QOL and more severe dyspnea agrees
and significantly extends previous descriptions. In a study
of 86 patients with COPD who answered a questionnaire
to identify GERD symptoms, Rascon-Aguilar et al. [28]
showed univariate differences in SF-36 QOL scores related
to the presence GERD symptoms, of the same magnitude
we detected. We extend those findings to show that the
association between reflux and poorer health-related QOL
(measured with the SGRQ questionnaire) persists in
multivariate analyses controlled for the effects of age, gen-
der, pulmonary function, current smoking, and BMI. Im-
portantly, the statistically significant effect in our data
persists after controlling for medication. Although GERD
therapy has been reported to improve QOL among the
general population [29], whether the same occurs among
COPD patients is unclear.
The current finding that GERD is significantly associated
with an exacerbation history also agrees with Hurst et al.
[7], who found an association with similar strength, but
who did not control for the effect of PPIs use. The consist-
ent results from different research designs in different pop-
ulations [7,30] point towards a significant relationship
between GERD and COPD exacerbations, and provide a
robust body of evidence to give strong consideration to
this factor as a potential disease-modifying intervention.
At least one small study has tested the concept of using
PPIs in COPD patients with no reflux symptoms [31], and
found a lower number of exacerbations after treatment
with lansoprazole. However, our data generate additional
questions about the potential use of PPIs to modify some
COPD outcomes, as the association differed in our study
depending on whether the outcome is QOL or exacerba-
tion frequency. We have highlighted to the possibility of
confounding-by-indication in the use of PPIs, which needs
to be addressed in future studies. An intriguing possibility,
which will require additional investigation, is that control
of acid aspiration improves QOL, but that the association
of GERD with increased exacerbation frequency relates
less closely to acid aspiration than to changes in the com-
munity structure of the lung microbiome [32], as sug-
gested by findings of higher frequency of pneumonia
among PPIs users in the general population [33,34].
Our study has several limitations. GERD diagnosis was
based on self-report of a physician diagnosis, not on pH
probe measures or specific questionnaires, which is poten-
tially subject to recall bias. Furthermore, even physician
diagnosis of GERD may not correlate with pH probe
testing. Additionally, the design of COPDGene is not
population-based, although it is inclusive of all levels of
COPD severity and includes subjects recruited across the
country at a wide variety of clinical centers. Whether the
associations between the outcomes of interest and GERD
therapy are restricted to PPIs, and not to antihistamines or
other anti-GERD medications, is difficult to answer; only
3.3% of our participants were exposed to antihistamines,
limiting the power for specific analysis. The current study
was not designed to ascertain compliance or persistence
on medications, and inquired about PPIs at inclusion, not
persistence on therapy, a factor potentially affecting results
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in longitudinal studies. The strengths of our study include
the extensive clinical and epidemiological characterization
of the participants; the number and heterogeneity of sub-
jects with versus without GERD included in the analysis;
and our efforts to control for confounders common in ob-
servational studies, such as clustering of comorbidities and
ignoring the effect of concurrent treatments.
We conclude that presence of GERD in COPD is asso-
ciated with increased symptoms, poorer health-related
QOL and increased frequency of exacerbations, even after
adjusting for a self-reported use of GERD-related medica-
tion. Because a history of GERD identifies COPD patients
at risk for poorer clinical outcomes, our results imply that
identification and management of GERD should be con-
sidered part of optimal clinical management of COPD.
Further research in the area is neccesary. Clinical trials to
identify and control GERD to improve COPD outcomes
should be considered.
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